COVID IP Waiver Attempts are Becoming Harder to Justify

By Gene Quinn
October 20, 2021

“As the COVID-19 pandemic continues to wane despite the world returning to business as usual it will become increasingly difficult, if not impossible, to justify an IP waiver.” week, at a meeting of the Council for Trade-Related Aspects of Intellectual Property Rights (TRIPS), World Trade Organization (WTO) members had an opportunity to engage in small group and bilateral meetings to discuss the proposals by South Africa and India to waive patent and trade secret protections relative to COVID-19 innovations, as well as the proposal from the European Union regarding the use of current TRIPS compulsory licensing provisions during a pandemic.

Some delegations believed the discussions were encouraging, while others expressed more skepticism, pointing out that a deal will not be achieved “unless delegations are able to make some real compromises.” See Members pursue convergence for IP COVID-19 response.

“The TRIPS Council is not yet in a position to agree on a concrete and positive conclusion at this point,” explained council chair Ambassador Dagfinn Sorli of Norway, who said he would again reconvene discussion of the issue at the next scheduled meeting on November 22-23.


The Case for Waiver is Becoming Moot

Time is waning for an agreement to be achieved, with most believing that the COVID-19 TRIPS Waiver must be agreed upon no later than the WTO’s 12th Ministerial Conference, which is to be held November 30 to December 3. The reason for this view is the simple fact that the COVID-19 pandemic is coming to an end, and any agreement reached by WTO members to circumvent intellectual property rights will have no impact on the pandemic whatsoever. So, if an agreement is not achieved by early December, all momentum will be lost by those who are seeking to have biotech and pharmaceutical innovators turn over their patents and trade secrets relating to COVID-19 innovations.

The good news is that the pandemic is coming under control, with the new cases, hospitalizations and deaths from the highly contagious Delta variant all dropping dramatically over the last five to seven weeks. In the U.S., for example, the peak of the Delta spike occurred on September 13, with 285,058 new cases that day and the 7-day moving average number of cases at 175,822 cases. Five weeks later, on October 18, the number of new cases dropped to 122,033 and the 7-day moving average number of cases is now 83,341, which corresponds to a 57.2% drop in the number of new cases and 52.3% drop in the 7-day moving average.

Worldwide, the Delta spike occurred on August 20 with 789,936 new cases and on August 26 with a 7-day moving average of 661,827 new cases.  On October 18, the number of new cases worldwide dropped to 425,922 and a 7-day moving average of 408,518, which corresponds to a 46.1% drop in new cases and a 38.3% drop in the 7-day moving average of new cases.

The data on U.S. hospitalizations is equally hopeful. The Delta spike in COVID-19 hospitalizations occurred on September 3 and had 94,368 patients hospitalized. As of October 16, the last day for which hospitalization data is available as of this writing, the number of patients hospitalized with COVID in the U.S. is 50,572. This corresponds to a 46.4% drop in hospitalizations nationwide over the last seven weeks.

An IP Grab

As the COVID-19 pandemic continues to wane despite the world returning to business as usual it will become increasingly difficult, if not impossible, to justify an IP waiver. As evidenced by calls to strip innovators of patent rights even before the first vaccines were achieved, these efforts have always been an opportunistic attempt by those who are fundamentally opposed to the very existence of patents to grab intellectual property from the pharmaceutical and biotech companies that have been researching and developing the technology behind these vaccines since at least 2003. See e.g. Settings for recombinant adenoviral-based vaccines, U.S. Patent No. 7,598,078 (filed by Crucell Holland B.V. in 2003 and later acquired by Johnson & Johnson).


Image Source: Deposit Photos
Image ID:471450802

The Author

Gene Quinn

Gene Quinn is a Patent Attorney and Editor and President & CEO ofIPWatchdog, Inc.. Gene founded in 1999. Gene is also a principal lecturer in the PLI Patent Bar Review Course and Of Counsel to the law firm of Berenato & White, LLC. Gene’s specialty is in the area of strategic patent consulting, patent application drafting and patent prosecution. He consults with attorneys facing peculiar procedural issues at the Patent Office, advises investors and executives on patent law changes and pending litigation matters, and works with start-up businesses throughout the United States and around the world, primarily dealing with software and computer related innovations. is admitted to practice law in New Hampshire, is a Registered Patent Attorney and is also admitted to practice before the United States Court of Appeals for the Federal Circuit. CLICK HERE to send Gene a message.

Warning & Disclaimer: The pages, articles and comments on do not constitute legal advice, nor do they create any attorney-client relationship. The articles published express the personal opinion and views of the author as of the time of publication and should not be attributed to the author’s employer, clients or the sponsors of Read more.

Discuss this

There are currently 2 Comments comments. Join the discussion.

  1. Greg DeLassus October 20, 2021 3:42 pm

    As the COVID-19 pandemic continues to wane despite the world returning to business as usual it will become increasingly difficult, if not impossible, to justify an IP waiver.

    Very true. With each passing day, the logic for a waiver becomes increasingly moot.

  2. Model 101 October 21, 2021 9:50 am

    Patents have nothing to do with vaccine distribution.

    Heart and soul is the issue.

Post a Comment

Respectfully add to the discussion.

Name *
Email *